Drug induced hepatitis with anti-tubercular chemotherapy: Challenges and difficulties in treatment

Kathmandu University Medical Journal

Volumn 5, Issue 18, 2007, Pages 256-260

  Kishore, P V ^a   Palaian, S ^a   Paudel, R ^a   Mishra, P ^a   Prabhu, M ^a   Shankar, P R ^a  

^a MANIPAL TEACHING HOSPITAL   (Nepal)

Author keywords

Adverse effects; Hepatotoxicity; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER NECROSIS; LIVER TOXICITY; NEPAL; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT FAILURE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY, CHRONIC; HUMANS;

EID: 41849099300     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. rd edition. Edinburgh: Churchill Livingston; 2003. p. 583-95.
2. National Tuberculosis Centre. Annual report of national tuberculosis control programme. , Nepal 2000/ 2001.
3. Harries A, Maher D, Uplekar M. National tuberculosis program of Nepal. A clinical manual. National tuberculosis center, Thimi, Bhaktapur, Nepal.
4. Anand AC, Seth AK, Paul M, Puri P. Risk Factors of hepatotoxicity during anti-tuberculosis treatment. MJAFI 200
5. Kumar A, Misra PK, Mehrolra R, Govil YC, Rana GS. Hepatotoxicity of rifampicin and isoniazid: is it all drug induced hepatitis? Am Rev Respir Dis 1991; 143: 1350-2.
6. Shakya R, Rao BS. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38(6): 1074-9.
7. Roy B, Chowdhury A, Kundu S. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001;16 (9):1033-7.
8. Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41(11):1226-32.
9. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 3: 201-6.
10. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a Public Health Tuberculosis Clinic. JAMA 1999; 281(11):1014-8.
11. CDC: Isoniazid hepatitis. MMWR 1993; 42: 545-7.
12. Nakajo MM, Rao M, Steiner P.: Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis. Pediatr Infect Dis J 1989; 8:649-50.
13. O'Brien RJ, Long MW, Cross FS, et al. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics 1983; 72:491-9.
14. Kucers A, Bennett N. The use of antibiotics, 4th. JB Lippincott Co, Philadelphia, PA, 1987, pp 1412-7.
15. McNeill L, Allen M, Estrada C, et al: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123:102-6
16. Jasmer RM, Saukkonen JJ, Blumberg HM, et al: Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137:640-7.
17. CDC: Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR 2003; 52 (31):735-9.
18. Tahaoglu K, Atac G, Sevim AT, et al: The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5 (1): 65-9.
19. Anonymous. BTS guidelines. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48.